Internal Medicine · Roseville, CA
NPI
1033281845
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
1600 Eureka Rd
Roseville, CA, 95661
Phone (916) 784-4000
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$1.0M
1,179 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Rani R Vatti prescribed most often to Medicare patients was Azelastine Hcl, with 147 prescriptions and refills. In total Rani R Vatti wrote 1,179 Medicare prescriptions that cost $1.0M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-03.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Azelastine Hcl Generic | 147 | 176 | 58 | $2,657 |
| Montelukast Sodium Generic | 117 | 352 | 48 | $1,293 |
| Fluticasone Propionate Generic | 103 | 154 | 37 | $2,495 |
| Breyna Budesonide/Formoterol Fumarate | 88 | 166 | 47 | $30K |
| Spiriva Respimat Tiotropium Bromide | 84 | 197 | 37 | $51K |
| Fasenra Pen Benralizumab | 63 | 112 | 14 | $339K |
| Prednisone Generic | 61 | 64 | 48 | $470 |
| Wixela Inhub Fluticasone Propion/Salmeterol | 61 | 181 | 34 | $18K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 53 | 55 | 35 | $872 |
| Alvesco Ciclesonide | 51 | 112 | 28 | $7,496 |
| Ipratropium Bromide Generic | 39 | 48 | 13 | $925 |
| Dupixent Pen Dupilumab | 31 | 35 | Under 11 | $113K |
| Epinephrine Generic | 26 | 26 | 22 | $3,151 |
| Famotidine Generic | 26 | 68 | Under 11 | $329 |
| Cromolyn Sodium Generic | 21 | 34 | Under 11 | $11K |
Brand drugs: 401 claims; generic drugs: 778 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Rani R Vatti were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.